Patients using Zepbound for weight management now have a simpler option for administering their medication. As reported by PharmaLive.com, Eli Lilly received FDA clearance for a redesigned injection pen that…
A first-of-its-kind Phase 3b study has shown that combining Eli Lilly’s Taltz (ixekizumab) with Zepbound (tirzepatide) delivers superior benefits for adults living with both active psoriatic arthritis (PsA) and obesity…
Roche has announced encouraging results from its Phase II trial of CT-388, an experimental obesity treatment that achieved placebo-adjusted weight loss of 22.5% over 48 weeks of treatment. This announcement…
In the shadows of his weight struggles, Sean Mulroney’s journey began at the staggering weight of 687 pounds in 2016. It was a weight that felt like a shackle, chaining…
According to a story from drugs.com, the biopharmaceutical company Palatin Technologies, Inc., which is specializing in the development of therapies that interact with the melanocortin receptor system, recently announced the…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
